- STAT+: Pharmalittle: We’re reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and moreKalshi, one of the world’s largest prediction market exchanges, plans to take bets on clinical trials and regulatory approvalsSTAT · 8d ago↗ source
- STAT+: FDA approves Merck’s oral PCSK9 drug, a firstKalshi allows bets on clinical trial outcomes, Eli Lilly buys a psychedelic medicine, and more biotech news from The ReadoutSTAT · 8d ago↗ source
- Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunoBraveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is lookin…